Bongolan, Mychill O.

HRN: 21-49-51  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/01/2022
CEFTRIAXONE 1G (VIAL)
07/01/2022
07/07/2022
IV
2g
OD
UTI
Waiting Final Action 
07/01/2022
CEFTRIAXONE 1G (VIAL)
07/01/2022
07/07/2022
IV
2gms
OD
UTI
Waiting Final Action 
07/01/2022
CEFTRIAXONE 1G (VIAL)
07/01/2022
07/07/2022
IV
2gms
OD
UTI
Waiting Final Action 
07/01/2022
AMPICILLIN 1GM (VIAL)
07/01/2022
07/07/2022
IV
2g
Q6
Threatened Preterm Labor
Waiting Final Action 
07/01/2022
GENTAMICIN 40MG/ML, 2ML (AMP)
07/01/2022
07/07/2022
IV
5mg/kg
Q6
Threatened Preterm Labor
Waiting Final Action 
07/05/2022
GENTAMICIN 40MG/ML, 2ML (AMP)
07/01/2022
07/05/2022
IV
372mg
OD
UTI; Threatened Preterm Labor
Waiting Final Action 
07/12/2022
AMPICILLIN 1GM (VIAL)
07/12/2022
07/12/2022
IV
2g
Q6
UTI, TC Preterm Labor
Waiting Final Action 
07/12/2022
GENTAMICIN 40MG/ML, 2ML (AMP)
07/05/2022
07/12/2022
IV
372mg
OD
UTI, Preterm Labor
Waiting Final Action 
07/12/2022
CLINDAMYCIN 150MG/ML, 4ML (AMP)
07/12/2022
07/19/2022
IVT
900mg
Q8H
R/o Sepsis
Waiting Final Action 
07/13/2022
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
07/13/2022
07/20/2022
IV
4.5g
Q8
G2P1 (1011); Complete Abortion; UTI
Waiting Final Action 
07/17/2022
CO-AMOXICLAV 625MG (TAB)
07/17/2022
07/23/2022
PO
625mg
TID
Puerperial Sepsis; Presumptive Ptb
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: